Enliven Therapeutics Inc. (ELVN)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$49.43

+4.64 (+10.36%)

Market Cap: $3.28B

Last updated: Nov 06, 2026 at 4:20 PM ET

Earnings

Performance (10Y)

Beat Rate

67%(18/27)

Avg Surprise

-2.78%

Streak

1 Q

Upcoming Estimates

Period ending Dec 31, 2026

EPS Consensus$-0.70

Range$-1.33 - $-0.16

8 analysts

Revenue Consensus

Range$0 - $0

10 analysts

Last 12 of 29 reported quarters and 1 upcoming estimate

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.70	$-1.33 - $-0.16	-	-	8	-	-
Sep 30, 2026Sep 26 Reported Nov 5, 2026Reported Nov 5	$-0.36	$-0.48	$-0.52 - $-0.38	+25.00%	Beat	8	0 2 30d	-12.5%
Jun 30, 2026Jun 26 Reported Aug 5, 2026Reported Aug 5	$-0.49	$-0.38	$-0.40 - $-0.29	-28.95%	Miss	3	No revisions (30d)	+0.0%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$-0.38	$-0.41	$-0.51 - $-0.31	+7.32%	Beat	2	No revisions (30d)	+33.3%
Dec 31, 2025Dec 25 Reported Mar 3, 2026Reported Mar 3	$-0.48	$-0.38	$-0.40 - $-0.35	-27.05%	Miss	2	No revisions (30d)	-4.3%
Sep 30, 2025Sep 25 Reported Nov 12, 2025Reported Nov 12	$-0.32	$-0.46	$-0.48 - $-0.45	+30.43%	Beat	2	No revisions (30d)	+33.3%
Jun 30, 2025Jun 25 Reported Aug 13, 2025Reported Aug 13	$-0.49	$-0.42	$-0.47 - $-0.37	-16.67%	Miss	2	No revisions (30d)	-19.5%
Mar 31, 2025Mar 25 Reported May 14, 2025Reported May 14	$-0.57	$-0.50	$-0.50 - $-0.50	-14.00%	Miss	0	No revisions (30d)	-5.6%
Dec 31, 2024Dec 24 Reported Mar 13, 2025Reported Mar 13	$-0.46	$-0.52	$-0.52 - $-0.52	+11.11%	Beat	0	No revisions (30d)	+2.1%
Sep 30, 2024Sep 24 Reported Nov 13, 2024Reported Nov 13	$-0.48	$-0.50	$-0.55 - $-0.44	+4.00%	Beat	8	No revisions (30d)	+5.9%
Jun 30, 2024Jun 24 Reported Aug 13, 2024Reported Aug 13	$-0.41	$-0.56	$-0.65 - $-0.49	+26.79%	Beat	6	No revisions (30d)	+0.0%
Mar 31, 2024Mar 24 Reported May 14, 2024Reported May 14	$-0.54	$-0.57	$-0.58 - $-0.55	+5.26%	Beat	3	No revisions (30d)	+32.5%
Dec 31, 2023Dec 23 Reported Mar 14, 2024Reported Mar 14	$-0.47	$-0.54	$-0.56 - $-0.51	+12.96%	Beat	4	No revisions (30d)	-138.8%

Key Metrics

Valuation
P/E Ratio	-28.91	EV/EBITDA	N/A
Price/FCF	-58.04x	FCF Yield	-1.72%
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-15.30%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	45.95x	Quick Ratio	45.95x
Trading Statistics
Beta	0.36	Avg Volume	1.64M
52-Week High	$62.32	52-Week Low	$14.79

Technical Indicators Dashboard

Moving Averages

SMA 10$45.02

SMA 20$42.59

SMA 50$47.25

SMA 200$43.22

EMA 10$45.26

EMA 20$44.45

EMA 50$46.34

EMA 200$42.80

MACD

Line: 0.27Signal: -0.80Hist: 1.07

ADX

ADX: 27.9+DI: 28.9-DI: 15.5

Aroon & PSAR

Aroon Up100.0

Aroon Down40.0

PSAR$42.67

Bollinger Bands

Upper Band$48.74

Lower Band$36.43

%B Position2890%(Upper)

Band Width1.06

RSI (14-Day)

Neutral

63.7

Momentum Oscillators

Stoch %K89.6

Stoch %D89.0

Williams %R-2.0

ROC (10d)19.1%

Momentum7.91

CCI (20d)148.0

MFI (14d)67.5

Volatility Measures

ATR (14d)$2.22(4.5%)

StdDev (20d)3.08

Hist Vol60.9%(High)

Volume Flow

VWAP$47.88

OBV56.9M

AD Line8.7M

CMF (20d)0.124

Volume Metrics

Avg Vol (20d)1.7M

Vol Ratio0.6x

VWMA (20d)$42.71

Pivot Points

R3$49.94

R2$48.84

R1$46.81

Pivot Point$45.71

S1$43.68

S2$42.58

S3$40.55

Advanced Oscillators

TSI3.14

Ultimate Osc60.0

KST-16.55

Financial Data

Quarter	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$316,000	$0	$0	$0	$440,000
Cost of Revenue	$0	$0	$0	$46,000	$0	$0	$0	$158,000	$0	$0	$0	$77,000
Gross Profit	$0	$0	$0	$-46,000	$0	$0	$0	$158,000	$0	$0	$0	$363,000

Operating Expenses	$36.05M	$37.21M	$27.82M	$34.28M	$25.10M	$28.58M	$31.69M	$26.90M	$27.07M	$24.60M	$25.99M	$22.73M
R&D	$28.02M	$29.00M	$20.69M	$21.25M	$18.23M	$21.49M	$24.89M	$20.72M	$21.26M	$18.83M	$19.97M	$17.91M
SG&A	$8.02M	$8.21M	$7.14M	$13.04M	$6.87M	$7.09M	$6.80M	$6.17M	$5.81M	$5.78M	$6.02M	$4.82M
Operating Income	$-36,045,000	$-37,209,000	$-27,823,000	$-34,285,000	$-25,096,000	$-28,584,000	$-31,693,000	$-26,896,000	$-27,068,000	$-24,603,000	$-25,987,000	$-22,729,000

Interest Income	$8.35M	$4.73M	$4.20M	$4.62M	$4.95M	$3.25M	$3.20M	$3.72M	$3.84M	$4.09M	$3.25M	$3.37M
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-27,703,000	$-32,485,000	$-23,627,000	$-29,667,000	$-20,148,000	$-25,335,000	$-28,544,000	$-24,053,000	$-23,156,000	$-19,718,000	$-22,738,000	$-19,370,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$232,000	$0	$0

Net Income	$-27,703,000	$-32,485,000	$-23,627,000	$-29,667,000	$-20,148,000	$-25,335,000	$-28,544,000	$-23,180,000	$-23,156,000	$-19,950,000	$-22,738,000	$-19,370,000

EBITDA	$-37,109,000	$-36,699,000	$-27,543,000	$-34,184,000	$-25,344,000	$-28,432,000	$-31,711,000	$-26,713,000	$-26,203,000	$-24,329,000	$-26,570,000	$-24,448,000
EBIT	$-36,056,000	$-37,217,000	$-27,823,000	$-34,285,000	$-25,096,000	$-28,586,000	$-31,740,000	$-27,769,000	$-26,995,000	$-23,804,000	$-25,988,000	$-22,738,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about ELVN

News

Form 4 Enliven Therapeutics Inc: Lori Anne Kunkel (Director) For: 30 October By Investing.com

This article reports on a Form 4 filing for Enliven Therapeutics Inc, indicating that Director Lori Anne Kunkel made a transaction on October 30. The filing is provided by Investing.com...

Investing.com India•Nov 4, 2026 1:22 AM ET11/4/26•Neutral

A director exercised options at $1.12 and $18.30 at Enliven Therapeutics (ELVN).

Lori Anne Kunkel, a director at Enliven Therapeutics (ELVN), exercised stock options on October 30, 2026. She acquired 3,741 common shares at $1.12 per share and 7,300 common shares at $18.30 per share. One option was...

Stock Titan•Nov 3, 2026 5:12 PM ET11/3/26•Neutral

BlackRock reports sole voting power over 5.1M Enliven Therapeutics (ELVN) shares.

BlackRock, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Enliven Therapeutics, Inc. (ELVN), reporting beneficial ownership of 5,206,581 common shares...

Stock Titan•Oct 27, 2026 5:10 PM ET10/27/26•Neutral

Enliven Therapeutics, Inc. Estimates – NASDAQ:ELVN

This article provides an overview of Enliven Therapeutics, Inc. (NASDAQ:ELVN) financials on TradingView, covering reported financial data and analyst estimates. Users can explore income statements, balance sheets...

TradingView•Oct 25, 2026 9:11 AM ET10/25/26•Neutral

Enliven Therapeutics CMO Collins sells $192,342 in ELVN stock By Investing.com

Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics, sold 5,000 shares of ELVN stock for $192,342 on October 19, 2026...

Investing.com South Africa•Oct 22, 2026 10:40 AM ET10/22/26•Neutral

ELVN Valuation and Fair Value

P/E: -28.9x
P/FCF: -58.0x
P/B: 4.4x

See GNG's fair value

ELVN Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -15.3%
FCF yield: -1.7%

ELVN Competitors

Company	Ticker
National HealthCare Corporation	NHC
Viridian Therapeutics Inc	VRDN
Tarsus Pharmaceuticals Inc	TARS
Dyne Therapeutics Inc	DYN
Celcuity LLC	CELC
Telix Pharmaceuticals Limited	TLX
Arcutis Biotherapeutics Inc	ARQT
Denali Therapeutics Inc	DNLI

Sector: Healthcare

ELVN Analyst Ratings

Consensus: Buy
Analysts: 12
Strong Buy: 1
Buy: 11
Hold: 0
Sell: 0
Strong Sell: 0

ELVN Bull Case vs Bear Case

Bull case

100.0% of ELVN's analyst ratings are Buy or Strong Buy.

ELVN Earnings: Beat Rate and Next Report

Beat rate: 4 of 8 quarters (50.0%)
Average surprise: -1.6%
EPS estimate (fiscal period ending Dec 31, 2026): $-0.70

ELVN Earnings Date

ELVN reports Mar 1, 2027, after the close. The date is estimated.

ELVN ETF Holders

GNG tracks 10 ETFs that hold ELVN. The largest weights:

State Street SPDR S&P Pharmaceuticals ETF (XPH), 1.56% of the fund
iShares Biotechnology ETF (IBB), 0.18% of the fund
Fidelity Enhanced Small Cap Core ETF (FESM), 0.05% of the fund
Vanguard Health Care Index Fund ETF Shares (VHT), 0.03% of the fund
Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.03% of the fund

Open the ETF Stock Exposure tool for ELVN

Frequently Asked Questions About ELVN

When does ELVN report earnings?

Enliven Therapeutics Inc. (ELVN) is expected to report earnings on Mar 1, 2027.

Does ELVN pay dividends?

Enliven Therapeutics Inc. (ELVN) does not currently pay a regular dividend.

What is ELVN's market cap?

Enliven Therapeutics Inc. (ELVN) has a market capitalization of $3.28B with a current stock price of $49.43.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In